Atopic Dermatitis

>

Latest News

Russell Libby, MD, FAAP
Discussing atopic dermatitis, roflumilast cream 0.15% with Russell Libby, MD, FAAP

January 2nd 2025

Russell Libby, MD, FAAP highlights some key benefits of roflumilast 0.15%, approved in 2024 to treat AD in patients aged 6 years and older.

Weekly review: Key pediatric dermatology approvals and more
Weekly review: Key pediatric dermatology approvals and more

December 23rd 2024

Contemporary Pediatrics’ top 3 FDA approvals of 2024
Contemporary Pediatrics’ top 3 FDA approvals of 2024

December 18th 2024

Image Credit: © JHVEPhoto - stock.adobe.com
Roflumilast 0.05% sNDA submitted to FDA for atopic dermatitis in children 2 to 5 years

December 16th 2024

FDA approves nemolizumab to treat atopic dermatitis in patients 12 years and upLatest revision | Image Credit: © Calin - © Calin - stock.adobe.com.
FDA approves nemolizumab to treat atopic dermatitis in patients 12 years and up

December 16th 2024

<12345
© 2025 MJH Life Sciences

All rights reserved.